HomeCompareEGRNY vs MRK

EGRNY vs MRK: Dividend Comparison 2026

EGRNY yields 34147.73% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EGRNY wins by $1.0717855393644993e+22M in total portfolio value
10 years
EGRNY
EGRNY
● Live price
34147.73%
Share price
$0.04
Annual div
$12.02
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.0717855393644993e+22M
Annual income
$10,656,466,585,714,744,000,000,000,000.00
Full EGRNY calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — EGRNY vs MRK

📍 EGRNY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEGRNYMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EGRNY + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EGRNY pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EGRNY
Annual income on $10K today (after 15% tax)
$2,902,556.82/yr
After 10yr DRIP, annual income (after tax)
$9,057,996,597,857,532,000,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, EGRNY beats the other by $9,057,996,597,857,532,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EGRNY + MRK for your $10,000?

EGRNY: 50%MRK: 50%
100% MRK50/50100% EGRNY
Portfolio after 10yr
$5.358927696822496e+21M
Annual income
$5,328,233,292,857,372,000,000,000,000.00/yr
Blended yield
99.43%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

EGRNY
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EGRNY buys
0
MRK buys
0
No recent congressional trades found for EGRNY or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEGRNYMRK
Forward yield34147.73%2.76%
Annual dividend / share$12.02$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$1.0717855393644993e+22M$56.8K
Annual income after 10y$10,656,466,585,714,744,000,000,000,000.00$9,798.13
Total dividends collected$1.0713819109694972e+22M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EGRNY vs MRK ($10,000, DRIP)

YearEGRNY PortfolioEGRNY Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$3,425,473$3,414,772.73$11,206$366.19+$3.41MEGRNY
2$1,096,862,531$1,093,197,275.43$12,650$502.35+$1096.85MEGRNY
3$328,323,285,434$327,149,642,525.61$14,407$694.19+$328323.27MEGRNY
4$91,870,493,472,810$91,519,187,557,395.90$16,585$967.82+$91870493.46MEGRNY
5$24,031,610,131,941,524$23,933,308,703,925,616.00$19,342$1,363.89+$24031610131.92MEGRNY
6$5,876,655,722,149,820,000$5,850,941,899,308,643,000.00$22,913$1,947.19+$5876655722149.80MEGRNY
7$1,343,466,526,931,397,600,000$1,337,178,505,308,697,300,000.00$27,662$2,823.89+$1343466526931397.75MEGRNY
8$287,132,226,887,877,040,000,000$285,694,717,704,060,450,000,000.00$34,159$4,173.35+$287132226887877056.00MEGRNY
9$57,372,717,691,821,160,000,000,000$57,065,486,209,051,124,000,000,000.00$43,337$6,308.80+$57372717691821162496.00MEGRNY
10$10,717,855,393,644,994,000,000,000,000$10,656,466,585,714,744,000,000,000,000.00$56,776$9,798.13+$1.0717855393644993e+22MEGRNY

EGRNY vs MRK: Complete Analysis 2026

EGRNYStock

China Evergrande Group, an investment holding company, primarily engages in the property development business in the People's Republic of China. It operates through four segments: Property Development, Property Investment, Property Management Services, and Other Businesses. It is involved in the development of residential properties, as well as other businesses, including property investment, property management, property construction, new energy vehicle, hotel operation, finance, internet, cultural tourism, and health businesses. The company was formerly known as Evergrande Real Estate Group Limited and changed its name to China Evergrande Group in July 2016. China Evergrande Group was incorporated in 2006 and is headquartered in Shenzhen, the People's Republic of China. China Evergrande Group operates as a subsidiary of Xin Xin (BVI) Limited.

Full EGRNY Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this EGRNY vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EGRNY vs SCHDEGRNY vs JEPIEGRNY vs OEGRNY vs KOEGRNY vs MAINEGRNY vs JNJEGRNY vs ABBVEGRNY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.